Ebola Risk in the United States: Assessing Probability and Preparedness

The probability of a large-scale Ebola outbreak in the United States is extremely low. Multiple layered defenses make sustained transmission highly unlikely:

1. Border and Travel Measures

• Enhanced entry screening for travelers from outbreak-affected regions (temperature checks, symptom questionnaires, contact info collection).
• CDC quarantine stations at 20 major ports of entry with authority to detain, isolate, or conditionally release travelers.

2. Healthcare System Readiness

• Tiered hospital network: Frontline facilities (identify/isolate), Assessment hospitals (evaluate/care until transfer), Treatment centers (specialized biocontainment units).
• Regional Ebola and Special Pathogen Treatment Centers (10 nationally) with advanced training, PPE, and waste management.
• Standardized protocols for PPE donning/doffing, lab safety, and waste inactivation.

3. Medical Countermeasures

• FDA-approved vaccine (Ervebo) for Zaire ebolavirus; stockpiled for outbreak response.
• Approved monoclonal antibody treatments (Inmazeb, Ebanga).
• Rapid diagnostic tests (e.g., OraQuick Ebola) for point-of-care detection.

4. Public Health Infrastructure

• Robust surveillance, contact tracing, and isolation capacity.
• Laboratory Response Network (LRN) for confirmatory testing.
• Interagency coordination (CDC, HHS, DoD, state/local health departments).

Historical Context

Four imported EVD cases occurred in the U.S. during the 2014–2016 epidemic (one index case, two nurse transmissions, one medevac). All were contained. No community transmission occurred.

Ongoing Vigilance

Risk is not zero. Global travel, zoonotic spillover, and viral evolution necessitate continued investment in preparedness, global health security partnerships, and rapid response capacity.